In the last trading session, 2.29 million shares of the Beam Therapeutics Inc (NASDAQ:BEAM) were traded, and its beta was 1.95. Most recently the company’s share price was $26.44, and it changed around $1.34 or 5.34% from the last close, which brings the market valuation of the company to $2.21B. BEAM currently trades at a discount to its 52-week high of $40.65, offering almost -53.74% off that amount. The share price’s 52-week low was $20.84, which indicates that the current value has risen by an impressive 21.18% since then.
Beam Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.76. If we narrow it down even further, the data shows that 0 out of 17 analysts rate the stock as a Sell; another 3 rate it as Overweight. Among the rest, 6 recommended BEAM as a Hold, whereas 8 deemed it a Buy, and 0 rated it as Underweight. Beam Therapeutics Inc is expected to report earnings per share of -1.22 for the current quarter.
Beam Therapeutics Inc (NASDAQ:BEAM) trade information
Instantly BEAM has showed a green trend with a performance of 5.34% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 29.99 on recent trading dayincreased the stock’s daily price by 11.84%. The company’s shares are currently up 6.61% year-to-date, but still down -11.39% over the last five days. On the other hand, Beam Therapeutics Inc (NASDAQ:BEAM) is 2.01% up in the 30-day period.
The consensus price target as assigned by Wall Street analysts is $48, which translates to bulls needing to increase their stock price by 44.92% from its current value. Analyst projections state that BEAM is forecast to be at a low of $37 and a high of $69.
Beam Therapeutics Inc (BEAM) estimates and forecasts
The year-over-year growth rate is expected to be 1.86%, up from the previous year.
Consensus estimates provided by 11 financial analysts predict the company will bring in an average of 14.68M in revenue for the current quarter. 11 analysts expect Beam Therapeutics Inc to make 15.52M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 7.41M and 11.77M respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 98.18%. Forecasts for the next quarter put sales growth at 31.81%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -20.88%. Beam Therapeutics Inc earnings are expected to increase by -9.24% in 2025, but the outlook is negative -2.49% per year for the next five years.
BEAM Dividends
Beam Therapeutics Inc’s next quarterly earnings report is expected to be released in April.
FARALLON CAPITAL MANAGEMENT LLC, with 9.6135% or 7.91 million shares worth $185.4 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
ARK ETF Tr-ARK Innovation ETF and Vanguard Total Stock Market Index Fund were the top two Mutual Funds as of Dec 31, 2024 . The former held 4.78 shares worth $126.42 million, making up 5.71% of all outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held roughly 2.34 shares worth around $61.79 million, which represents about 2.79% of the total shares outstanding.
